跳至主要内容

High Throughput ADME Study of New Drug Discovery

For the development of innovative drugs, the process consists of three stages and four steps: target discovery, characterization and evaluation (biological target phase); Discovery and optimization of lead compounds (drug discovery phase); ADMET (absorption, distribution, metabolism, excretion and toxicity), PK, PD studies (drug discovery and development phase); clinical trial (drug development stage).

High Throughput ADME Study of New Drug Discovery

The use of high-throughput ADME screening technology can quickly identify the lead compounds, but by combining the chemical structure of the compound library, the first is the problem of poor structural diversity, which reduces the success rate of compound development; followed by compounds of poor drug resistance, so that a large number of Compounds were eliminated during ADME screening, increasing the cost of the experiment. Over the past 20 years, although new technologies have emerged in the drug discovery phase, there has been no substantial increase in the number of new compound entities listed each year. In addition, most of the currently established high-throughput methods are related to the type of compound structure tested and are not fully versatile.

high-throughput adme screening

In the drug discovery phase, there are three ways: in silico or computational method, in vitro and in vivo;

Computational Method: Although many in vivo and in vitro micro-, simplistic, and automated experimental methods have been developed that have been greatly improved in terms of analytical time, labor intensity, and number of compounds to be treated, the experimental method is still considered to be slow , costly, and the need for the synthesis of candidate compounds. The virtual screening method can be seen as an alternative method for predicting the ADME characteristics of candidate compounds. The method has high throughput or ultra-high throughput. This method includes small intestine absorption prediction; blood brain barrier (BBB) permeability prediction and Prediction of metabolic stability.

In Vitro: Over the past 10 years, in vitro methods have been widely used for the determination of permeability, bioavailability, metabolic stability, drug interactions and physico-chemical parameters. The advantage of in vitro methods is that a model of high throughput or medium flux can be established by means of micro fabrication and automation, followed by the use of tissue components from the human body to study the differences between humans and animals, to improve the success rate of drug research and development. However, in vitro studies lack the influencing factors such as blood flow, biochemical factors and various transporters in vivo. In addition, the organic solvents used in the formulation of the compounds may mask the solubility of the drug in vivo and affect the activity of the drug metabolizing enzymes. This method includes: Evaluation model of small intestine absorption; metabolic stability study; Determination of physical and chemical parameters and Study on drug interactions.

In Vivo:  In the drug discovery phase, in vivo studies have been very different from in vivo studies in terms of dose, blood collection, and animal quantity. At this stage, the purpose of in vivo research is mainly to optimize the lead compounds and to make further recommendations on the further study of candidate compounds in combination with in vitro studies. In vivo study is a low-throughput, time-consuming, large sample size and uneconomical research methods, but in vivo studies have in vitro research institute without blood flow, various factors and other factors, is the new drug research indispensable One. In vivo studies, there are two general approaches to improving the flux: increasing the speed of analysis and reducing the number of samples. There are two things should be noticed in this method, to improve sample analysis speed and reduce the number of samples.

Related Articles:

Preclinical ADME Studies

Medicilon’s Drug ADME/PK Assays Services

ADME Pharmacokinetics Studies

High Throughput ADME Study of New Drug Discovery

Medicilon's Drug ADME/PK Assays Services

Drug absorption, distribution, metabolism and excretion (pharmacokinetics)

评论

此博客中的热门博文

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

  Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the   preclinical study   of the antibody-drug-conjugate (ADC)  DXC005, including the   pharmacology study ,   DMPK study   and the   safety evaluation . Medicilon has previously completed integrated  preclinical research  on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...

Medicilon assisted Hangzhou DAC Biotech in approval of clinical study of ADC drug DAC-002

  On July 20, 2020, DAC Biotech’s new   ADC drug development , TROP2-ADC—DAC-002 was approved of clinical study by NMPA. for the indication of solid malignant tumor. Medicilon completed   preclinical pharmacokinetic  and toxicological studies in this project, accelerating the development process. DAC-002 is an ADC anti-Trop2 monoclonal antibody conjugated by an intelligent ligand against Tubulysin B analogue. It is used to treat Trop2 triple negative breast cancer, small cell lung cancer, non-small cell lung cancer and pancreatic cancer.Trop2 can promote the proliferation, invasion, metastasis and diffusion of tumor cells, and its high expression is closely related to the shortening of survival time and poor prognosis of tumor patients. Therefore, it is of great significance to study anti-tumor drugs targeted by Trop2. Reference: Medicilon Assists - The first China-made targeting folic acid receptor FRα ADC injection BAT8006 was approved for clinical use Medicilon As...

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...